CD4 independent entry by HIV-2: properties of an alternative cell surface receptor.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CD4 independent entry by HIV-2: properties of an alternative cell surface receptor.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo14 (abstract no. MoA 0049). Unique Identifier : AIDSLINE ICA8/92400005
Clapham P; McKnight A; Simmons G; Cordell J; Dean C; Weiss R; Chester Beatty Labs, Institute of Cancer Research, London, UK.

Abstract: INTRODUCTION AND OBJECTIVES: We have recently shown that a substrain of HIV-2ROD (LAV-2/B) efficiently infected CD4-negative human RD, Daudi and Raii cell lines. Other HIV-2 strains either failed (e.g. CBL-20) to infect or infected less efficiently (e.g. SBL6669) than LAV-2/B, although most HIV-2 isolates tested induced syncytia if treated with soluble CD4. These results suggest that HIV-2 can use an alternative cell surface receptor independently or in conjunction with CD4 (J. Virol. In press). Here we studied the distribution and properties of this receptor on human cell types. We also present a preliminary characterization of rat monoclonal antibodies raised against LAV-2ROD that inhibit CD4-independent entry. METHODS: HIV-2 infectivity and cell to cell fusion assays in the presence and absence of inhibitory CD4 mAbs were used to assess expression of non-CD4 receptors on different cell types. RESULTS: The receptor for HIV-2 CD4-independent entry was found to be expressed mainly on primary and established haematapoietic cells. Several rat mAbs raised to LAV-2ROD recombinant gp105 specifically inhibited CD4-independent entry, but did not affect CD4-dependent entry, whether CD4 was present in a soluble form or expressed at the cell surface. CONCLUSIONS: An alternative cell surface receptor that permits HIV-2 infection was found to be mainly expressed on haematapoietic cell types. These results may have implications for the in vivo tropisms of HIV-2

Keywords: Animal Antibodies, Monoclonal/IMMUNOLOGY Antigens, CD4/IMMUNOLOGY Burkitt's Lymphoma/PATHOLOGY Cell Fusion Comparative Study Cytopathogenic Effect, Viral Hematopoietic Stem Cells/MICROBIOLOGY Human HIV-2/CLASSIFICATION/*PHYSIOLOGY Rats Receptors, HIV/*PHYSIOLOGY Tumor Cells, Cultured/MICROBIOLOGY Tumor Stem Cells/MICROBIOLOGY ABSTRACT
921230
M92C5342

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .